Application of CGE in cell and gene therapy by Kerstin Pohl | Mar 12, 2025 | Biopharma, BioPhase 8800 system, BlogsIn a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Tips and tricks from our application experts: AAV analysis with CE by Peter Holper | Jan 24, 2025 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemPeter Holper, Staff Applications Scientist at SCIEX, US, shares his tips and tricks on AAV analysis using CE with the BioPhase 8800 system and the PA 800 Plus system.
Plasmid manufacturing: Setting up your CGT programs for success by Kerstin Pohl | Nov 15, 2024 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemPlasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in plasmid manufacturing, provided insights into the process and an outlook on the future.
Discover high-quality mRNA integrity and purity assessments by Kerstin Pohl | May 22, 2024 | Biopharma, BioPhase 8800 system, BlogsLipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA (mRNA) products, most notably used for production of vaccines against the recent SARS-CoV-2 pandemic.
Addressing stability challenges of mRNA-LNP therapies by Kerstin Pohl | May 13, 2024 | Biopharma, BioPhase 8800 system, BlogsIn a recent webinar, available on demand, Jingtao Zhang (PhD), Scientific Director, and Daniel Turner, Scientist at Catalent® Pharma Solutions, presented their approaches to addressing stability challenges of mRNA-based products.
A new approach for comprehensive AAV evaluation including full and empty analysis by Kerstin Pohl | Apr 16, 2024 | Biopharma, BioPhase 8800 system, BlogsCertain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well characterized.
Better mRNA-LNPs: encapsulation efficiency, mRNA integrity and purity, lipid N-oxides and beyond by Kerstin Pohl | Mar 14, 2024 | Biopharma, BioPhase 8800 system, Blogs, ZenoTOF 7600 systemLipid nanoparticles (LNPs) are widely used vehicles for mRNA-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause functional loss of the mRNA cargo.